| human | Q5 |
| P6178 | Dimensions author ID | 0736270275.90 |
| P691 | NL CR AUT ID | xx0139592 |
| P496 | ORCID iD | 0000-0002-9470-5292 |
| P3829 | Publons author ID | 2021476 |
| P1053 | ResearcherID | S-7276-2017 |
| P1153 | Scopus author ID | 57117804500 |
| P214 | VIAF ID | 174936905 |
| P1343 | described by source | Medvik | Q99413897 |
| P108 | employer | Institute of Clinical and Experimental Medicine | Q12021666 |
| P734 | family name | Svobodová | Q62067709 |
| Svobodová | Q62067709 | ||
| Svobodová | Q62067709 | ||
| P735 | given name | Eva | Q829665 |
| Eva | Q829665 | ||
| P106 | occupation | researcher | Q1650915 |
| transplant surgeon | Q7834824 | ||
| immunologist | Q12119633 | ||
| P21 | sex or gender | female | Q6581072 |
| Q85455427 | Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: a case report |
| Q40734481 | Molecular diagnostics identifies risks for graft dysfunction despite borderline histologic changes |
| Q40310759 | Novel insights into pretransplant allosensitization in heart transplant recipients in the contemporary era of immunosuppression and rejection surveillance. |
| Q50717107 | Pre-transplant donor-specific Interferon-gamma-producing cells and acute rejection of the kidney allograft. |
| Q36248860 | Sequential Targeting of CD52 and TNF Allows Early Minimization Therapy in Kidney Transplantation: From a Biomarker to Targeting in a Proof-Of-Concept Trial. |
Search more.